KEGG   DRUG: Serplulimab
Entry
D12751                      Drug                                   
Name
Serplulimab (USAN/INN);
Hetronifly (TN)
Formula
C6388H9830N1690O2000S44
Exact mass
143624.7155
Mol weight
143713.46
Sequence
(Heavy chain)
QVQLVESGGG LVKPGGSLRL SCAASGFTFS NYGMSWIRQA PGKGLEWVST ISGGGSNIYY
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCVSYY YGIDFWGQGT SVTVSSASTK
GPSVFPLAPC SRSTSESTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
LSSVVTVPSS SLGTKTYTCN VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP
PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS QEEMTKNQVS
LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS
CSVMHEALHN HYTQKSLSLS LGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCKASQDVT TAVAWYQQKP GKAPKLLIYW ASTRHTGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYTIPWTFGG GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H130-L214, H143-H199, H222-H'222, H225-H'225, H257-H317, H363-H421, H'22-H'96, H'130-L'214, H'143-H'199, H'257-H'317, H'363-H'421, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Remark
ATC code: L01FF12
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  Type
Monoclonal antibody
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
  Network
nt06537  TCR/BCR signaling
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF12 Serplulimab
      D12751  Serplulimab (USAN/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12751  Serplulimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D12751  Serplulimab (USAN/INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12751
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12751
Other DBs
CAS: 2231029-82-4
PubChem: 497621164
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system